Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Biosimilars: SOP for mRNA Transcript Analysis (RT-PCR) – V 2.0

Posted on By


Biosimilars: SOP for mRNA Transcript Analysis (RT-PCR) – V 2.0


Standard Operating Procedure for mRNA Transcript Analysis using RT-PCR in Biosimilar Development

Department Biosimilars
SOP No. SOP/BS/019/2025
Supersedes SOP/BS/019/2022
Page No. Page 1 of 13
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To define the standard procedure for analyzing mRNA transcripts of biosimilar genes in transfected cell clones using reverse transcription polymerase chain reaction (RT-PCR).

2. Scope

This SOP applies to molecular biology and analytical teams responsible for evaluating transcriptional expression of biosimilar genes in cell line development processes.

3. Responsibilities

  • Molecular Biologist: Performs total RNA isolation, cDNA synthesis, and RT-PCR.
  • Research Assistant: Maintains reagents, prepares reaction setups, and performs gel analysis.
  • QA Officer: Verifies experimental records and ensures compliance with documentation standards.
See also  Biosimilars: SOP for Productivity Testing in Small-Scale Cultures - V 2.0

4. Accountability

The Head of Molecular Biology is accountable for ensuring transcript analysis is accurate, validated, and compliant with biosimilar development protocols.

5. Procedure

5.1 Total RNA Isolation

  1. Harvest cells (≥1 × 106) and wash with ice-cold PBS.
  2. Lyse cells using TRIzol reagent or column-based RNA extraction kits.
  3. Quantify RNA using a spectrophotometer (A260/A280 ratio ~2.0).
  4. Check RNA integrity on 1% agarose gel (28S/18S rRNA bands).

5.2 DNase Treatment

  1. Treat 1 µg of RNA with DNase I to remove genomic DNA contamination.
  2. Incubate at 37°C for 30 minutes and inactivate DNase as per reagent protocol.

5.3 cDNA Synthesis

  1. Use 1 µg of DNase-treated RNA in a 20 µL reverse transcription reaction.
  2. Include oligo(dT) or random hexamer primers, dNTPs, and reverse transcriptase enzyme.
  3. Incubate as follows:
    • 25°C for 10 minutes
    • 42°C for 60 minutes
    • 70°C for 15 minutes (enzyme inactivation)
See also  Biosimilars: SOP for Adaptation of Cells to Serum-Free Media - V 2.0

5.4 PCR Amplification of Target Transcript

  1. Set up PCR using gene-specific primers (e.g., for rhEPO or mAb light chain).
  2. Prepare 25 µL reaction mixtures using cDNA, Taq polymerase, and buffer system.
  3. Thermal cycling conditions:
    • Initial denaturation: 95°C for 3 min
    • 35 cycles: 95°C for 30 sec, 58°C for 30 sec, 72°C for 1 min
    • Final extension: 72°C for 5 min

5.5 Gel Electrophoresis and Documentation

  1. Run PCR product on 1.5% agarose gel with ethidium bromide or GelRed.
  2. Capture gel image and note band size and intensity.
  3. Record results in the RT-PCR Expression Log (Annexure-1).

6. Abbreviations

  • RT-PCR: Reverse Transcription Polymerase Chain Reaction
  • RNA: Ribonucleic Acid
  • cDNA: Complementary DNA
  • PBS: Phosphate Buffered Saline

7. Documents

  1. RT-PCR Expression Log (Annexure-1)
  2. RNA Quality Assessment Sheet (Annexure-2)
See also  Biosimilars: SOP for Limiting Dilution Cloning - V 2.0

8. References

  • WHO TRS 999 – Molecular Characterization of Cell Lines
  • MIQE Guidelines for RT-PCR Reporting
  • ICH Q5B – Analysis of Expression Constructs

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: RT-PCR Expression Log

Date Clone ID Gene Target Band Size (bp) Result Operator
03/05/2025 CL-BS-019 rhEPO 520 Detected Sunita Reddy

Annexure-2: RNA Quality Assessment Sheet

Date Clone ID Concentration (ng/µL) A260/A280 Integrity Operator
02/05/2025 CL-BS-019 320 2.01 Intact Rajesh Kumar

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Included RNA integrity check and DNase treatment steps Annual SOP review
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: BA-BE Studies: SOP for Sample Storage at -20°C and -70°C – V 2.0
Next Post: Creams: SOP for Inspecting Sealing Quality in Cream Packaging Machines – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version